Lv11
70 积分 2023-07-20 加入
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial
5小时前
已关闭
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
6天前
已完结
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
1个月前
已完结
TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases
1个月前
已完结
A break in mitochondrial endosymbiosis as a basis for inflammatory diseases
1个月前
已完结
Psoriasis Prevalence in Adults in the United States
1个月前
已完结
Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series
2个月前
已关闭
Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents
2个月前
已完结
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
2个月前
已完结
First Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis
4个月前
已完结
皖公网安备34019202002308
